Correlation of plasma and neuroimaging biomarkers in Alzheimer's disease

被引：15
|
作者：
Brickman, Adam M. [1 ,2 ,3 ]
Manly, Jennifer J. [1 ,2 ,3 ]
Honig, Lawrence S. [1 ,2 ,3 ]
Sanchez, Danurys [1 ,2 ,3 ]
Reyes-Dumeyer, Dolly [1 ,2 ,3 ]
Lantigua, Rafael A. [1 ,4 ]
Vonsattel, Jean Paul [1 ,4 ,5 ]
Teich, Andrew F. [1 ,5 ]
Kang, Min Suk [1 ]
Dage, Jeffrey L. [6 ,7 ]
Mayeux, Richard [1 ,2 ,3 ]
机构：
[1] Columbia Univ, Vagelos Coll Phys & Surg, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY 10027 USA
[2] Columbia Univ, Vagelos Coll Phys & Surg, GH Sergievsky Ctr, New York, NY 10027 USA
[3] Columbia Univ, Vagelos Coll Phys & Surg, Dept Neurol, New York, NY USA
[4] New York Presbyterian Hosp, New York, NY USA
[5] Columbia Univ, Vagelos Coll Phys & Surg, Dept Med, New York, NY USA
[6] Columbia Univ, Vagelos Coll Phys & Surg, Dept Pathol & Cell Biol, New York, NY USA
[7] Indiana Univ, Sch Med, Stark Neurosci Res Inst, Indianapolis, IN USA
来源：
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY | 2022年 / 9卷 / 05期
基金：
美国国家卫生研究院;
关键词：
DEMENTIA; TAU;
D O I：
10.1002/acn3.51529
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Blood-based phosphorylated tau (Ptau) 181 and 217 biomarkers are sensitive and specific for Alzheimer's disease. In this racial/ethnically diverse cohort study, participants were classified as biomarker positive (Ptau+) or negative (Ptau-) based on Ptau 181 and 217 concentrations and as cognitively impaired (Sym) or unimpaired (Asym). The four groups, Ptau-/Asym, Ptau+/Asym, Ptau-/Sym, and Ptau+/Sym, differed by age, APOE-4 allele frequency, total tau, neurofilament light chain, and cortical thickness measured by MRI. Our results add to increasing evidence that plasma Ptau 181 and 217 concentrations are valid Alzheimer's disease biomarkers in diverse populations.
引用
收藏
页码：756 / 761
页数：6
相关论文
共 50 条
  • [21] Biomarkers and phenotypic expression in Alzheimer’s disease: exploring the contribution of frailty in the Alzheimer’s Disease Neuroimaging Initiative
    Marco Canevelli
    Ivan Arisi
    Ilaria Bacigalupo
    Andrea Arighi
    Daniela Galimberti
    Nicola Vanacore
    Mara D’Onofrio
    Matteo Cesari
    Giuseppe Bruno
    GeroScience, 2021, 43 : 1039 - 1051
  • [22] A combined proteomic and neuroimaging approach to identifying biomarkers in Alzheimer's disease
    Thambisetty, M
    Hye, A
    Foy, C
    Poppe, M
    Archer, N
    Campbell, J
    Ward, M
    Lovestone, S
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2005, 238 : S303 - S304
  • [23] Longitudinal neuroimaging biomarkers differ across Alzheimer's disease phenotypes
    Sintini, Irene
    Graff-Radford, Jonathan
    Senjem, Matthew L.
    Schwarz, Christopher G.
    Machulda, Mary M.
    Martin, Peter R.
    Jones, David T.
    Boeve, Bradley F.
    Knopman, David S.
    Kantarci, Kejal
    Petersen, Ronald C.
    Jack, Clifford R., Jr.
    Lowe, Val J.
    Josephs, Keith A.
    Whitwell, Jennifer L.
    BRAIN, 2020, 143 : 2281 - 2294
  • [24] Seven-Tesla MRI and neuroimaging biomarkers for Alzheimer's disease
    Ali, Rohaid
    Goubran, Maged
    Choudhri, Omar
    Zeineh, Michael M.
    NEUROSURGICAL FOCUS, 2015, 39 (05)
  • [25] The search for neuroimaging biomarkers of Alzheimer's disease with advanced MRI techniques
    Li, Tie-Qiang
    Wahlund, Lars-Olof
    ACTA RADIOLOGICA, 2011, 52 (02) : 211 - 222
  • [26] Neuroimaging modalities in the detection of Alzheimer's disease-associated biomarkers
    Dang, Chun
    Wang, Yanchao
    Li, Qian
    Lu, Yaoheng
    PSYCHORADIOLOGY, 2023, 3
  • [27] Detection of β-amyloid positivity in Alzheimer's Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers
    Tosun, Duygu
    Veitch, Dallas
    Aisen, Paul
    Jack, Clifford R., Jr.
    Jagust, William J.
    Petersen, Ronald C.
    Saykin, Andrew J.
    Bollinger, James
    Ovod, Vitaliy
    Mawuenyega, Kwasi G.
    Bateman, Randall J.
    Shaw, Leslie M.
    Trojanowski, John Q.
    Blennow, Kaj
    Zetterberg, Henrik
    Weiner, Michael W.
    BRAIN COMMUNICATIONS, 2021, 3 (02)
  • [28] Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease
    Dickerson B.C.
    Sperling R.A.
    NeuroRX, 2005, 2 (2): : 348 - 360
  • [29] Neuroimaging in Alzheimer's disease
    Fox, N. C.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2006, 16 : S197 - S198
  • [30] Alzheimer's disease neuroimaging
    Whitwell, Jennifer L.
    CURRENT OPINION IN NEUROLOGY, 2018, 31 (04) : 396 - 404
12345